Form 4: Director Maha Radhakrishnan Receives Stock Options

Entrada Therapeutics director Maha Radhakrishnan was granted 19,000 stock options as part of standard equity compensation.

Summary

• Director Maha Radhakrishnan acquired 19,000 stock options in Entrada Therapeutics, Inc. (TRDA).
• The options have an exercise price of $5.97 per share.
• The grant date for these options is June 10, 2026.
• The options are set to expire on June 10, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• Results in potential future dilution of existing shareholders upon exercise of the options.

Risks

• Market volatility affecting the value of the underlying common stock.
• Potential for future dilution if options are exercised.

Future Outlook

The options vest on the earlier of the one-year anniversary of the grant date or the issuer's next annual meeting of stockholders.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board expertise.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical director compensation packages for mid-cap biotechnology firms.

Stakeholder Impact

• Minor potential dilution for existing shareholders.

Next Steps

• Vesting of options on the earlier of June 10, 2027, or the next annual meeting of stockholders.

Key Dates

Keywords

Entrada Therapeutics, TRDA, Form 4, Insider Trading, Stock Options, Director Compensation